ECMO in adults: what is its role?
Jeffrey Wassermann MD FRCPC C. David Mazer MD FRCPC I N this issue of the Journal, Voelckel et al. 1 report on two cases of blunt thoracic trauma with severe acute respiratory failure (ARF) in which extracorporeal membrane oxygenation (ECMO) was successfully employed.
In the first case, a 29 yr old man involved in a motor vehicle accident sustained a haemopneumothorax and severe bilateral pulmonary contusions. Within seven hours post injury, his oxygenation had deteriorated (PaO 2 =21 mm Hg; FiO 2 1.0) and ECMO was subsequently used for support of oxygenation. In the second case, a 12 yr old boy was hit by a falling tree and sustained a pneumothorax and bilateral pulmonary contusions. His oxygenation subsequently deteriorated and a tracheobronchial disruption was ultimately diagnosed. The patient was immediately placed on ECMO for respiratory support as well as to facilitate repair of the tracheobronchial injury. Both patients made full recoveries and left hospital.
The first report of the use of ECMO for ARF was by Hill in 1972. 2 Since that time, numerous studies and case reports 3 " 8 have been published on its use in patients with severe ARF of various aetiologies including those with trauma related respiratory failure. In these reports, ECMO is variably described using the synonyms Extracorporeal Lung Assist (ECLA or ELA) and/or Extracorporeal Life Support (ECLS), all of which refer to the same process.
The results for ECMO in neonates with ARF have been positive with survival rates as high as 90% in patients with meconium aspiration syndrome. Overall, survival rates in neonates have been approximately 80%. 9 The UK collaborative randomized trial of neonatal ECMO 10 revealed an overall survival of 59%, but when patients with congenital diaphragmatic hernia (a group with a notoriously poor outcome) were excluded, the overall rate increased to 80% also. Therefore, ECMO has become a standard therapy in neonates with severe ARF.
In adults however, results have been variable and much less encouraging. ECMO has been employed primarily for ARF in patients with the Acute Respiratory Distress Syndrome (ARDS). Several published reports 3 " 8 including the NIH-sponsored randomized controlled trial of ECMO in adults with ARF 11 have failed to demonstrate a benefit in adults. The NIH study demonstrated survival rates of only 10% in both the ECMO and control groups. Of the 90 patients studied, there were six posttraumatic patients, none of whom survived.
Although there were various case reports of the successful use of ECMO in adult patients over the ensuing years after the NIH trial, a report in 1986 of the use of ECMO solely for CO 2 removal (extracorporeal CO 2 removal or ECCO 2 R) revealed promising results (48.8% survival in 43 adults with ARDS) and renewed interest in the use of ECMO for ARF. 12 However, a subsequent randomized trial of ECCO 2 R demonstrated no survival benefit of this therapy. 13 The therapeutic principle of ECMO is to ensure adequate oxygenation by partially or totally replacing the lungs' function in gas exchange thus allowing minimization of mechanical ventilation and its attendant risks of O 2 toxicity as well as baro-and volutrauma. This may provide a window to support the lungs' healing process. Generally, it should be remembered that ECMO is an adjunct to oxygenation and ventilation and not a therapy in itself.
The ECMO circuit consists of three main components: pumps, oxygenators, and heat exchangers, but also requires cannulae for vascular access, filters, pressure gauges and in-line oxygen saturation monitors as well as personnel for constant monitoring of the patient and system, a detailed protocol, and an experienced team.
Blood flow can generally be directed in one of two directions: veno-venous or veno-arterial. Venous blood is withdrawn, O 2 is added and/or CO 2 is removed, and then reinfused into the patient. ECMO usually provides approximately 30-50% of the cardiac output but in situations of cardiac failure, veno-arterial access can be employed to bypass a larger percent-age of cardiac output. Mechanical ventilation is usually continued during ECMO but usually at a rate of 4-6 breaths per minute with peak inspiratory pressures of 30-35, FlO 2 0.5 and PEEP of 10 -15 to prevent atelectasis and to keep arterial oxygen saturation >80-90%. Dialysis can be added in-line when necessary.
In general, ECMO may be indicated for patients with respiratory failure of a reversible aetiology but of such severity to yield an expected mortality rate of ^80% (based on physiological variables) and who are not responding to standard medical management (Table) . The lack of adherence to standard indications for use in adults is probably one of the explanations for the variability in success among different reports. The timing of ECMO use also seems to be important in determining its success, and may also account for some of the variability in results. Patients in whom ECMO is initiated within five days of mechanical ventilation tend to be most likely to respond, whereas those in whom ECMO is begun after 10 days do very poorly.
Complications of ECMO can be attributed to mechanical and patient related factors. Patient related complications include neurological, renal and hepatic dysfunction, sepsis, haemolysis and bleeding. It is recommended that patients on ECMO be heparinized to an activated clotting time (ACT) of between 120 and 200 sec to avoid clot formation in the oxygenators and this, along with the platelet destruction and activation of the clotting and fibrinolytic system by contact of blood with a foreign surface, account for the high rate of bleeding in patients on ECMO (approximately 68-75%). 3, 14 This high rate of bleeding has been a key concern in the use of ECMO in trauma patients and should, of course, be a major consideration in deciding whether to employ it in a trauma patient with severe ARF. However, it should be noted that ECMO has been used in patients with intracerebral contusions without worsening neurologic function. The use of centrifugal pumps, heparin-bonded circuits, 7 ' 8 ' 15 newer bio-artificial coatings and even of nitric oxide in the oxygenator gas may decrease or alleviate the need for heparin altogether. 16 As mentioned above, ECMO is not a therapy to treat diseased lungs but a life support system that may allow the lungs time to heal. Ultimately, the ability of the lungs to heal or the avoidance of multiorgan failure determines survival 14 which remains at only 40-50% for patients with ARDS regardless of therapy. Although there are no treatment modalities currently available to speed lung healing, there are several other methods of respiratory support that may be useful in improving ventilation and oxygenation in patients with severe ARF. These include higher PEEP levels, inhaled nitric oxide, prone positioning, pressure-limited ventilation, permissive hypercapnia, selective lung ventilation, high frequency jet or oscillatory ventilation, and liquid ventilation. Many of these have also not shown a reduction in mortality from ARF or ARDS but are generally less invasive and labour-intensive, and can be performed at most centres.
Voeckel et al. do not provide us with full details of ventilation strategies immediately before initiation of ECMO. Certainly their patients had severe thoracic trauma and ARF but we do not know if they exhausted all other modes of ventilatory support first. Therefore, we do not know if their patients might have had equally good outcomes without the use of ECMO.
In summary, ECMO has been shown to reduce mortality in neonates with severe ARF and has become standard therapy in this group of patients. Many adult patients with ARF have also survived after ECMO treatment. However, if ECMO were a drug, the data available to date would not justify regulatory approval for its use in adults. Thus, at present ECMO remains an invasive, expensive, and unproven adjunct to the treatment of adults with severe acute respiratory failure. 8 ont ete publiees concernant son emploi aupres de patients presentant une severe IRA d'etiologie diverse, y compris rinsuffisance respiratoire liee a un traumatisme. Dans ces articles, l'OEC recoit des appellations variees a partir de synonymes comme Assistance pulmonaire extracorporelle (APEC) et/ou Maintien extracorporel des fonctions vitales (MEFV), tous se referant au meme procede.
Les resultats de l'usage de l'OEC chez les nouveaunes ont ete positifs puisque le taux de survie est aussi eJeve que 90 % chez les bebes qui souffrent du syndrome d'aspiration meconiale. Globalement, le taux de survie chez les nouveau-nes a ete d'environ 80 %. 9 Un essai clinique britannique, multicentrique et randomise 10 , de l'OEC neonatale revele un taux de survie global de 59 %, mais lorsqu'on exclue les patients qui presentent une hernie diaphragmatique congenitale (un groupe reconnu comme ayant une faible chance de survie), le taux s'eleve a 80 %. En consequence, l'OEC est devenue une therapie standard chez les nouveau-nes souffrant d'une severe IBA.
Chez les adultes toutefois, les resultats ont ete variables et beaucoup moins encourageants. L'OEC a ete utilisee principalement pour l'IRA chez les patients qui presentment un syndrome de detresse respiratoire aigue (SDRA). Plusieurs rapports publies 3 " 8 , induant l'etude clinique randomisee sur l'OEC dans le traitement de l'IRA 11 chez les adultes, commanditee par les NIH (National Institutes of Health), n'ont pu demontrer de benefice chez ces patients. L'etude americaine a demontre des taux de survie de 10 % seulement dans les deux groupes, celui de l'OEC et le groupe temoin. Des 90 patients a l'etude, six ont ete trait.es a la suite d'un traumatisme et aucun d'entre eux n'a survecu.
Quoiqu'il y ait eu diverses observations d'utilisation reussie de l'OEC chez des patients adultes dans les annees qui ont suivi l'essai de la NIH, un article de 1986 sur l'usage de l'OEC seulement pour Pextraction de CO 2 (extraction extracorporelle de CO 2 ou EECCO 2 ) revele des resultats prometteurs (48,8 % de survie chez 43 adultes atteints de SDRA) et renouvelle l'interet pour l'usage de l'OEC comme traitement de l'IRA. 12 Toutefois, un essai randomise d'EECCO 2 , realise plus tard, n'a pu demontrer que cette therapie offrait quelque benefice pour la survie. Generalement, l'OEC est indiquee pour des patients qui presentent une insuffisance respiratoire d'etiologie reversible, mais d'une severite telle qu'on rapporte un taux de mortalite attendu de 80 % (base sur des variables physiologiques), et qui ne repondent pas au traitement medical standard (Table) . L'absence d'adhesion a des indications normalisees pour son usage aupres des adultes constitue probablement une des explications de la variabilite de son succes au travers des differents articles. Le moment choisi pour utiliser l'OEC est aussi determinant et peut influencer la variabilite des resultats. Les patients soumis a une OEC en deca de cinq jours apres le debut de la ventilation mecanique ont beaucoup plus tendance a repondre au traitement, alors que chez ceux ou l'OEC debute apres 10 jours les resultats sont pauvres.
Les complications de l'OEC peuvent etre attributes a des facteurs mecaniques et des facteurs lies au patient. Les complications reliees au patient sont neurologiques, renales et hepatiques, la septicemie, l'hemolyse et les saignements. On recommande que les patients places en OEC recoivent de Pheparine pendant un temps de coagulation active (TCA) de 120 a 200 s afin d'eviter la formation de caillot dans les oxygenateurs. Ce qui, avec la destruction des plaquettes et l'activation de la coagulation et du systeme fibrinolytique par le contact du sang avec une surface etrangere, rend compte du haut taux de saignement chez les patients sous OEC (approximativement 68-75 %). 3 ' 14 Ces saignements ont ete une preoccupation cle lors de Putilisation de l'OEC chez des patients victimes de traumatisme et ils devraient, bien sur, faire l'objet d'une consideration majeure quand on decide si on emploie l'OEC chez un patient souffrant d'une severe IRA. Cependant, on doit souligner que l'OEC a ete utilisee chez des patients presentant des contusions intracerebrales sans amoindrir la fonction neurologique. L'emploi de pompes centrifuges, de tubulures a heparine greffee, Comme on l'a dit deja, l'OEC n'est pas une therapie pour traiter les maladies pulmonaires mais un systeme qui maintient les fonctions vitales et permet ainsi aux poumons de guerir. Finalement, la possibility que les poumons se retablissent et Pevitement de defaillance multiorganique determinent la survie 14 qui demeure a seulement 40-50 % pour les patients atteints du SDRA, quelle que soit la therapie. Bien qu'il n'y ait pas de modalites therapeutiques offertes actuellement pour hater la guerison des poumons, il y a quelques autres methodes d'assistance respiratoire qui peuvent etre utiles pour ameliorer la ventilation et l'oxygenation chez les patients atteints d'une severe IRA. Ces methodes comprennent des niveaux plus eleves de PEP, Pinhalation d'oxyde nitrique, l'installation en decubitus ventral, la ventilation a pression limitee, l'hypercapnie permissive, la ventilation pulmonaire selective, la ventilation a jet ou oscillatoire et la ventilation liquide. Nombre de ces methodes n'ont pas non plus montre de reduction de mortalite causee par l'IRA ou le SDRA, mais elles sont generalement moins effractives et exigent moins d'effort tout en etant applicables dans la plupart des centres.
Voeckel et coll. ne nous donnent pas beaucoup de details sur les strategies de ventilation immediatement avant le debut de l'OEC. II est certain que leurs patients ont eu un traumatisme thoracique severe et de l'IRA, mais nous ne savons pas si les chercheurs ont d'abord epuise tous les autres recours a l'assistance ventilatoire. Nous ne savons done pas si leurs patients auraient pu connaitre une aussi bonne evolution sans l'emploi de l'OEC.
En resume, on a montre que l'OEC reduit la mortalite chez les nouveau-nes qui presentent une severe IRA et qu'elle est devenue une therapie standard pour ce groupe de patients. De nombreux patients adultes souffrant d'IRA ont aussi survecu apres un traitement d'OEC. Cependant, si l'OEC etait un medicament, les donnees actuellement disponibles ne justifieraient pas Papprobation de son usage regulier chez les adultes. Ainsi, aujourd'hui, l'OEC demeure un complement effractif, cher et non prouve, du traitement des adultes qui souffrent d'une severe insuffisance respiratoire aigue. 
